On May 26, 2023 Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, reported that new data will be presented at the upcoming ASCO (Free ASCO Whitepaper) and SNMMI 2023 Annual Meetings, covering clinical and pre-clinical results in multiple oncology indications (Press release, Clarity Pharmaceuticals, MAY 26, 2023, View Source [SID1234632138]). The data showcases the breadth of Clarity’s TCT platform of developing multiple products to treat a multitude of cancers with high unmet medical needs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Clarity’s Executive Chairman, Dr Alan Taylor, commented, "The ASCO (Free ASCO Whitepaper) and SNMMI Annual Meetings are the most prestigious conferences in oncology and nuclear medicine, respectively. We are delighted that our data has been accepted for presentation at these major forums. The abstracts accepted for presentation highlight the exciting possibilities of our next-generation TCT radiopharmaceuticals, addressing some of the challenges of the current-generation of radiopharmaceutical products and expanding the platform into multiple malignancies. We look forward to further developing our existing as well as novel TCT products as we get closer to our ultimate goal of improving treatment outcomes for children and adults with cancer."
Data to be presented at 2023 ASCO (Free ASCO Whitepaper) and SNMMI Annual Meetings
Product
Abstract Title`
Authors
Conference
64Cu SAR-bisPSMA
64Cu-SAR-bisPSMA (PROPELLER) Positron Emission Tomography (PET) Imaging in Patients With Confirmed Prostate Cancer
Eva Lengyelova, Veronica Wong, Nat Lenzo, Michelle Parker, Louise Emmett
2023 ASCO (Free ASCO Whitepaper) Annual Meeting
Session title: Genitourinary Cancer — Prostate, Testicular, and Penile
Session date: 3rd June
Session time: 8am-11am
Poster Board: 133
Abstract number: 5039
64Cu SAR-bisPSMA
Comparison of PET/CT in Subjects with Confirmed Prostate Cancer Using 64Cu SAR-bisPSMA and 68Ga PSMA-11
Eva Lengyelova, Veronica Wong, Nat Lenzo, Michelle Parker, Louise Emmett
2023 SNMMI Annual Meeting
64Cu/67Cu SAR-bisRGD
Cu-64/Cu-67 SAR-bisRGD as a theranostic for cancer
Ellen van Dam, Lachlan McInnes, Benjamin Blyth, Jessica Van Zuylekom, Buck E. Rogers, Cristian Wieczorek Villas Boas, Yi Rao, Jason S. Lewis, Kurt Gehlsen, Jeff Norenberg, Matt Harris
2023 SNMMI Annual Meeting
64Cu SAR-5B1 and SAR-5B1 and 64Cu SAR-bisRGD
Copper-67 based targeted radiotherapy primes immunologically cold pancreatic adenocarcinoma for immunotherapy
Yi Rao, Tara Viray, Ellen Van Dam, Kurt Gehlsen, Matt Harris, Lachlan Mclnnes, Jeff Norenberg, Jason S Lewis
2023 SNMMI Annual Meeting
Poster abstracts will be available on Clarity’s official website after their presentation at the 2023 ASCO (Free ASCO Whitepaper) and SNMMI Annual Meetings: claritypharmaceuticals.com/pipeline/scientific_presentations